To access this material please log in or register

Register Authorize

Use of Bivalirudin at performance of percutaneous coronary intervention in patients with acute coronary syndrome

Movsesiants M. Yu., Mironkov A. B., Maltsev A. V., Kiselev D. G., Abugov S. A.

Keywords: bivalirudin, myocardial infarction, acute coronary syndrome, transcutaneous coronary intervention

DOI: 10.18087/rhj.2012.5.1706

At carrying out of percutaneous coronary intervention (PCI) in patients with ACS, antiplatelet and anticoagulant therapies are very important. Administration of indirect thrombin inhibitors – unfractionated or low molecular weight heparins in combination with aspirin, clopidogrel, and, sometimes, with platelet glycoprotein IIb / IIIa receptors blockers – at carrying out of PCI in patients with ACS is connected with high risk of bleedings. A new anticoagulant, which belongs to the class of direct thrombin inhibitor, Bivalirudin has been introduced to the clinical practice. The properties of this drug are not inferior to that of indirect thrombin inhibitors in prevention of adverse heart events, but the results of its administration demonstrate a considerable decrease in bleedings in patients with ACS who undergo PCI. This article reviews researches and first experience of administration of this drug in patients with ST segment elevation MI and non-ST segment elevation ACS at PCI.
  1. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF / AHA / SCAI Guideline for Percutaneous Coronary Interven­tion. A report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58 (24):e44–122.
  2. Steg PG, Huber K, Andreotti F et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32 (15):1854–1864.
  3. Maraganore JM, Bourdon P, Jablonski J et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry. 1990;29 (30):7095–7101.
  4. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol. 1998;82 (8B): 12P-18P.
  5. Sciulli TM, Mauro VF. Pharmacology and clinical use of bivalirudin. Ann Pharmacother. 2002;36 (6):1028–1041.
  6. Ramana RK, Lewis BE. Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin. Vascular Health and Risk Management. 2008;4 (3):493–505.
  7. Fox I, Dawson A, Loynds P et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost. 1993;69 (2):157–163.
  8. Lidón RM, Théroux P, Juneau M et al. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation. 1993;88 (4 Pt 1):1495–1501.
  9. Bates ER. Bivalirudin: an anticoagulant option for percutaneous coronary intervention. Expert Rev Cardiovasc Ther. 2004;2 (2):153–162.
  10. White H; Hirulog and Early Reperfusion or Occlusion (HERO) – 2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001;358 (9296):1855–1863.
  11. Cannon CP, Maraganore JM, Loscalzo J et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993;71 (10):778–782.
  12. Sharma GV, Lapsley D, Vita JA et al. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol. 1993;72 (18):1357–1360.
  13. Topol EJ, Bonan R, Jewitt D et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation. 1993;87 (5):1622–1629.
  14. Bittl JA, Chaitman BR, Feit F et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142 (6):952–959.
  15. Bittl JA, Strony J, Brinker JA et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med. 1995;333 (12):764–769.
  16. Lincoff AM, Kleiman NS, Kottke-Marchant K et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002;143 (5):847–853.
  17. Lincoff AM, Bittl JA, Harrington RA et al. REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb / IIIa blockade compared with heparin and planned glycoprotein IIb / IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289 (7):853–863.
  18. Gibson CM, Morrow DA, Murphy SA et al. TIMI Study Group. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006;47 (12):2364–2373.
  19. Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355 (21):2203–2216.
  20. Edmond JJ, French JK, Aylward PE et al; for the HERO-2 Investigators. Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2. Eur Heart J. 2007;28 (12):1418–1424.
  21. Stella JF, Stella RE, Iaffaldano RA et al. Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Invasive Cardiol. 2004;16 (9):451–454.
  22. Stone GW, Witzenbichler B, Guagliumi G et al. HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358 (21):2218–2230.
  23. Waksman R, Wolfram RM, Torguson RL et al. Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH – a multicenter clinical trial. J Invasive Cardiol. 2006;18 (8):370–375.
  24. Gibson CM, Ten Y, Murphy SA et al. Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention A REPLACE-2 analysis. Am J Cardiol. 2007;99 (12):1687–1690.
  25. Chamberlin JR, Lewis B, Leya F et al. Successful treatment of hepa­rin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol. 1995;11 (6):511–514.
  26. Mahaffey KW, Lewis BE, Wildermann NM et al. ATBAT Investigators. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 2003;15 (11):611–616.
Movsesiants M. Yu., Mironkov A. B., Maltsev A. V. et al. Use of Bivalirudin at performance of percutaneous coronary intervention in patients with acute coronary syndrome. Russian Heart Journal. 2012;11(5):259-263.

To access this material please log in or register

Register Authorize
Ru En